OF4949-I and II inhibited aminopeptidase B from Ehrlich ascites carcinoma in a competitive way and the Ki value for both against L-arginine-/3-naphthylamide was 8 x 10"9 m. Inhibition by I and II of various exopeptidases and endopeptidases was examined. OF4949-I and II both strongly inhibited leucine aminopeptidase and enkephalin-degrading aminopeptidase; I also inhibited enkephalinase B.
The inhibitory effects of various derivatives of I and II on aminopeptidase B activity, showedthat the terminal amino and carboxamide groups are essential for activity.
Wehave reported on the fermentation, isolation, structure, biological activity, and biosynthesis of the cyclic peptides OF4949-I (1), II (2), III, and IV obtained from the culture broth of Penicillium rugulosum OF4949.1~3) Compounds 1 and 2 strongly inhibit aminopeptidase B (AP-B) from Ehrlich ascites carcinoma (EAC) cells and enhance delayed-type hypersensitivity (DTH) to sheep red blood cells in mice.0
To find a derivative with yet stronger enzyme inhibition, and immunological enhancement, and also to elucidate the relationship between structure and biological activity, we prepared various derivatives of 1 and2.
Here, the inhibition by 1 and 2 of several exopeptidases and endopeptidases and the inhibition of AP-B by derivatives synthesized from 1 and 2 were studied.
Materials and Methods
Compounds 1 and 2 were prepared from the fermentation broth of P. rugulosum OF4949 as described in a previous paper.1} Enzymes Aminopeptidase from rat kidney was prepared by a modification of the method of Oya et al.°The enzyme preparation was purified by fractionation with (NH4)2SO4 [30-55 % saturation for AP-B5>6) and leucine aminopeptidase (Leu-AP), and 55-80% saturation for aminopeptidase A (AP-A)7) and dipeptidyl aminopeptidase IV (DAP-IV)4)]. AP-B from various tumor cell lines maintained in the peritoneal cavity of mice was prepared by the same methods for the EACAP-B as described before.1} Carboxypeptidase A (CP-A) from bovine pancreas and carboxypeptidase B (CP-B) from porcine pancreas were purchased from the Sigma Chemical Co., St. Louis, U.S.A. Dipeptidyl carboxypeptidase (DCP) from Escherichia coli K-12 was prepared by the method of Deutch.8) Carboxypeptidase P (CP-P) from Penicillium janthinellum was supplied by Dr. Sadaji Yokoyama of Takara Shuzo Co., Ltd. The enkephalinase A (EKL-A) and enkephalinase B (EKL-B) and the enkephalindegrading aminopeptidase (EDAP) used here were partly purified from rat cerebrum by the procedure of Gorenstein and Snyder.9) Trypsin from bovine pancreas was purchased from Difco Laboratories, Detroit, U.S.A.; achymotrypsin from bovine pancreas, papain from papaya, and elastase from porcine pancreas were purchased from Sigma; pepsin from porcine stomach mucosaand thermolysin from Bacillus thermoproteolyticus were from Nakarai Chemicals, Ltd., Kyoto, Japan.
Cells
Mouse leukemias L1210 and P388 were maintained in DBA/2mice (females, 6 weeks old) and EACand Sarcoma-180 (S-180) in out-bred ddY (females, 6 weeks old) or ICR mice (females, 6 weeks old) by ip inoculation every 7 days. The cultured cell line, L5178Y (mouse leukemia) was propagated in RPMI1640 medium (Nissui Pharmaceutical Co., Tokyo, Japan) with 10% fetal calf serum (FCS). CHO/Pro", Chinese hamster ovary cells, were propagated in the alpha modification of Eagle's minimal essential medium(a-MEM, GIBCO Laboratories, Grand Island, U.S.A.) with 10% FCS. Mouse spleen lymphocytes and peritoneal macrophages were prepared from CDFi mice (females, 6 weeks old).
Substrates (20) and iV-formyl-II (22) were prepared as described in another paper.2) For purification of derivatives, preparative HPLCwas done on a Nucleosil 30C18 column (4 x 150 mm) with 0.1 m citrate buffer, pH 5.7, containing 5 to 20% acetonitrile, and the eluate was desalted on an XAD-2column with 50% MeOH.
I-Butyl Ester (4): A solution of 200 mg of 1 in a mixture of 10 ml of Af,N-dimethylformamide (DMF) and 10ml of 2n butanolic HC1 was stirred at room temp for 15 hours to give 72.9 mg of 4 as a white powder. IR iw cm"1 1735 (ester carbonyl);^NMR(CD3OD+DMSO-</6) d 0.8-1.1 (3H, m, CH3), 1.2-1.9 (4H, m), 3.86 (3H, s, OCH3).
I-Benzyl Ester (5): To a solution of 200mg of 1 in a mixture of 10ml of benzyl alcohol and 20 ml of benzene was added 100 mg of/7-toluenesulfonic acid, and the mixture was refluxed for 4 hours. A mixture of ether -w-hexane (1 : 1) was added to this solution and the precipitate was filtered to give 343.7 mg of product. The product was purified by preparative HPLC, giving 83.5 mg of 5 as a white powder. XH NMR (CD3OD+DMSO-</6) 8 3. (25): To a solution of 1 (200mg) dissolved in 10ml of 0.1 m phosphate buffer, pH 7.0, was added 40 ml of acetoaldehyde. The solution was stirred at room temp for 10 minutes; then 100 mg of sodium cyanoborohydride (NaBH3CN) was added, and stirring was continued for 20 minutes, to give 129 mg of 13 as a colorless powder. Compound 25 (28.6 mg) was obtained from 50 mg of 2 in the same way. JV-Dimethyl-II (24): To a suspension of 50mg of 2 in 5 ml of 0.1 m phosphate buffer (pH 7.0), 0.1 ml of formaldehyde was added and the whole was stirred at room temp for 10 minutes. Then 30 mgof NaBH3CN was added to the solution and the mixture stirred for another 60 minutes, giving 24.6 mg of24 as a colorless powder. XH NMR(CD3OD-fD2O) 8 2.52 (6H, s, CH3x2).
iV-Diethyl-II (26): Compound 2 (50 mg) was dissolved in a mixture of 5 ml of 0.1 m phosphate buffer, pH 7.0, and 0.05 ml of acetoaldehyde and stirred for 10 minutes at room temp; then 30 mg of NaBH3CN was added and the whole was stirred for another 60 minutes, to give 31.4 mg of 26 as a colorless powder. 'U NMR (CD3OD) 8 1.06 (6H, t, CH3 x2).
Results
Compounds 1 and 2 strongly inhibit EACAP-B from use of L-Arg-/3-NA as a substrate.1} The effect of these two inhibitors on AP-Bfrom various other mammaliancells or tissues was examined. Both 1 and 2 considerably inhibited enzymes that hydrolyze L-Arg-/3-NA from a wide range of sources (Table 1) . Compounds 1 and 2 inhibited enzymes that originated from S-180, CHO/Pro", and L5178Y about as strongly as for the enzyme from EAC, but were weaker against enzymes from L1210, P388 lymphoma, mouse spleen lymphocytes, mouse peritoneal macrophages, rat liver homogenate, and rat kidney. Neither 1 nor 2 inhibited the hydrolysis of L-Lys-/3-NA by EAC AP-B.
The kinetics of the hydrolysis of L-Arg-^-NA by EAC AP-B in the presence of 1 and of 2 were investigated as a function of the concentration of the substrate. Lineweaver-Burk plots of the data indicated that both 1 and 2 were competitive inhibitors. The Michaelis-Menten constant, Km, for L-Arg-/3-NA was 7.0x10~5 m. The inhibition constant, Ki, for both 1 and 2 against L-Arg-/3-NA was 8xlO"9M.
To elucidate the participation of chelation in the inhibitory reaction, zinc ion was added to the reaction mixture of EACAP-B and inhibitors. The inhibition of 0.25 mMof 1,10-phenanthroline or ethylenediaminetetraacetic acid (EDTA) was almost reversed by addition of 0.1 mMof zinc ion, but the inhibition of 1 and 2 was not, whenthe amounts in moles of zinc ion and inhibitors were the same as in the previous experiments. The effects of 1 and 2 on other exopeptidases and endopeptidases were also tested. The concentrations required for 50% inhibition, that is, IC50, for each enzyme are shown in Table 2 . Compound 1 inhibited Leu-AP from rat kidney and EDAPfrom rat cerebrum, and inhibited EKL-Bsomewhat less. Compound 2 also inhibited Leu-AP and EDAP, but had almost no effect on EKL-B. Compounds 1 and 2 did not inhibit the activity of AP-A, DAP-IV, CP-A, -B, or -P, DCP, EKL-A, or endopeptidases such as trypsin, a:-chymotrypsin, elastase, kallikrein, papain, pepsin, or thermolysin, even at the concentration of 300 /^g/ml. These results indicated that 1 and 2 were selective inhibitors of AP-B, Leu-AP, and EDAP.
The inhibition by various derivatives synthesized from compounds 1 and 2 of EACAP-B was examined. IC50 by partially modified derivatives are shown in Table 3 . Inhibition by derivative 16 with a butyl group substituted for the Rx was less than that by 1 with a methyl group or 2 with a proton. From comparison of 1 with 14 and 7 with 15, we found that substitution of bromide for the benzene-ring R2 proton markedly lowered the activity. The effects of substituting something for the terminal amino, carboxamide, or terminal carboxyl groups of 1 and 2 were then examined. Replacement of the R3 proton, the R4 proton, or both with a methyl, ethyl, formyl, or acetyl group produced iV-alkyl or JV-acyl derivatives (ll~13 and 22~26) with little or no activity. Wefound that the inhibitory effect of derivative 7 (18) with a carboxyl group substituted for the carboxamide group (X) of 1 (2) was much less than the effect of the parent compound. When we compared 1 with 3, 7 with 8, 2 with 17, and 18 with 19, the derivatives with carboxyl methyl ester substituted for the carboxyl group had equal or stronger activity than the parent compound. However, the substituted compounds with a carboxybutyl ester, carboxybenzyl ester, alcohol, or carboxamide group (4~6 and 20) had somewhat less activity than 1 or 2.
Discussion Hopus et al.5'6) found that AP-B purified from rat liver can liberate only the TV-terminal basic amino acids, arginine and lysine, from peptide substrates. Ellis and Perry14) reported the presence of two different forms of AP-B, arginyl arylamidase and lysyl arylamidase, in bovine anterior pituitary glands; the forms can be distinguished by their requirement for thiol compounds for activation and different sensitivities to puromycin. AP-Bis distributed in various organs of animals, not only in the cells but also on cell surfaces, as are alkaline phosphatase, esterase, glucosidase, and other aminopeptidases.15'16) In our experiment, 1 and 2 strongly inhibited AP-B from various mammalian cells or tissues that hydrolyzed L-Arg-/3-NA, but had almost no effect on the hydrolysis of L-Lys-/3-NA. This result suggests that 1 and 2 may be a kind of AP-B inhibitor unlike puromycin; puromycin is more sensitive to lysyl arylamidase than to arginyl arylamidase.14)
Kinetic studies of both 1 and 2 with EAC AP-B and L-Arg-/3-NA showed that the inhibition was competitive with the substrate. The inhibition by 1 and 2 was not reversed when zinc ion was added. The results indicated that 1 and 2 may act by a mechanism different from the chelating reaction of 1 , Enkephalins are degraded by aminopeptidases18~20) as well as by EKL-A and -B and angiotensinconverting enzyme.21~23) Compound1 strongly inhibited EDAPand EKL-B. From this result, we think that 1 might enhance morphine analgesia, as do bestatin and^-hydroxy-2*S,3i£-3-amino-2-hydroxyphenyl-4-phenylbutanoyl-L-leucine.24)
The difference in the inhibition by 1 and 2 of EKL-B may be due to the difference between the methoxyl and hydroxyl groups.2) Neither 1 nor 2 inhibited hydrolysis by AP-A, DAP-IV, CP-A, -B, or -P, DCP, EKL-A, or any endopeptidase tested. The inhibitory effect on peptidase by 1 and 2 of these enzymes resembled that of bestatin.25) From our examination of various synthetic derivatives of 1 and 2, it seems that the terminal amino and carboxamide groups are essential for activity. As reported in the first and second papers,1't he difference in the activity of 1 (2) and the deoxy derivatives, OF4949-III (IV), of alcoholic hydroxyl group, suggested that the alcoholic hydroxyl group is also important in inhibition.
